Recombinant Human KGF/FGF-7 Protein, CF

Measured in a cell proliferation assay using Ba/F3 mouse pro B cells transfected with human FGF RIIb. The ED50 for this effect is 4.00-40.0 ng/mL.

2 μg/lane of Recombinant Human KGF/FGF‑7 Protein (Catalog # 11537-KG) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 15-18 kDa, under reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human KGF/FGF-7 Protein, CF Summary

• Additional Information: CHO expressed
• Details of Functionality: Measured in a cell proliferation assay using Ba/F3 mouse pro B cells transfected with human FGF RIIb. The ED₅₀ for this effect is 4.00‑40.0 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human KGF/FGF-7 protein
  Ser55-Thr194
• Accession #: P21781.1
• N-terminal Sequence: Ser55
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 16 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 15-18 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in MOPS, Na₂SO₄ and EDTA with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute 10 μg size at 100 μg/mL and the other sizes at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human KGF/FGF-7 Protein, CF

• FGF7
• FGF-7
• fibroblast growth factor 7HBGF-7
• HBGF7
• HBGF-7
• Heparin-binding growth factor 7
• keratinocyte growth factor
• KGF
• KGFfibroblast growth factor 7 (keratinocyte growth factor)

Background

Fibroblast growth factor 7 (FGF7), also known as keratinocyte growth factor (KGF), is a member of the FGF family of secreted glycoproteins which are involved in key roles from development, morphogenesis, and angiogenesis to wound healing and tumorigenesis (1-4). FGF7, along with FGF3, FGF10, and FGF22, form a subfamily of the larger FGF family whose expression is restricted to cells of mesenchymal origin and function as paracrine growth factors for nearby epithelial cells (1). The FGF family is characterized by a core heparin-binding FGF domain of approximately 120 amino acids (aa) that exhibits a conserved beta -trefoil structure (2). Mature human FGF7 shares 96% and 92% aa sequence identity with mouse and rat FGF7, respectively. FGF7 signals only through the IIIb splice form of the receptor FGFR2, whose expression is restricted primarily to epithelial cells (5). FGF7 is noticeably upregulated in response to damage to skin or internal structures and is proposed to help speed-up wound healing (6). Deletion of FGF7 affects kidney development, producing abnormally small ureteric buds and fewer nephrons (7). FGF7 has been proposed as a potential cancer therapeutic by targeting the intermolecular interaction site between FGF7 and FGFR2b (3). Additionally, the use of FGF7 is being explored as novel treatment options for cartilage diseases, such as Osteoarthritis and Rheumatoid arthritis (8). An N-terminally truncated version of FGF7 with improved thermal stability, named Palifermin (brand name Kepivance), is approved for treatment for reducing and/or healing damages caused by cancer chemotherapy and radiotherapy, such as severe oral mucositis (OM) (9,10).

1. Mohammadi, M. et al. (2005) Cytokine Growth Factor Rev. 16:107.
2. Itoh, N. and D.M. Ornitz (2008) Dev. Dyn. 237:18.
3. Vadija, R. et al. (2016) J. Chem. Biol. 9:69.
4. Itoh, N. and D.M. Ornitz (2004). Trends Genet. 20:563.
5. Steiling, H. and S. Werner (2003) Curr. Opin. Biotechnol. 14:533.
6. Geer, D.J. et al. (2005) Am. J. Pathol. 167:1575.
7. Qiao, J. et al. (1999) Development 126:547.
8. Zhang, X. et al. (2023) Life Sci. 326:121804.
9. Hsu, E. et al. (2006) PEDS 19:147.
10. Sadeghi, S. et al. (2021)  Int. J. Biol. Macromol. 191:1175.

Bioinformatics

• Uniprot:
  • P21781.1()